| |
HLA-A*24:02
|
HLA-A*24:02
|
p-value
|
|---|
|
matched
|
unmatched
|
|---|
|
Number of patients
|
36
|
27
| |
|
Age, years
|
62.9 ± 2.1
|
63.4 ± 2.1
|
0.7072
|
|
Gender
| | |
0.3074
|
|
Male
|
17 (47.2%)
|
17 (63.0%)
| |
|
Female
|
19 (52.8%)
|
10 (37.0%)
| |
|
Stage (UICC)
| | |
0.7439
|
|
III
|
7 (19.4%)
|
5 (18.5%)
| |
|
IV
|
26 (72.2%)
|
21 (77.8%)
| |
|
Recurrence
|
3 (8.3%)
|
1 (3.7%)
| |
|
Tumor marker
| | | |
|
CEA
|
369.2 ± 247.9
|
8.5 ± 2.1
|
0.1722
|
|
CA19-9
|
3870.1 ± 1972.7
|
3643.2 ± 1444.7
|
0.0718
|
- Abbreviations: HLA human leukocyte antigen, UICC Union for International Cancer Control, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9
